Cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) compared to lamivudine as first line treatment of chronic hepatitis B (CHB) in the UK

被引：0

作者：

Veenstra, DL

Sullivan, SD

Dusheiko, GM

Jacobs, M

Lewis, GJ

Patel, KK

机构：

[1] Univ Washington, Seattle, WA 98195 USA

[2] Royal Free Hampstead NHS Trust, London, England

[3] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England

[4] Hoffmann La Roche Inc, Nutley, NJ 07110 USA

来源：

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A120 / A120

页数：1